Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Genitourinary 1Breast 1

Conditions

Ovarian Neoplasms 2Endometrial Neoplasms 2Prostatic Neoplasms 1Neoplasms 1Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 35Carboplatin 24Specimen Handling 20Cyclophosphamide 18Magnetic Resonance Spectroscopy 17fludarabine 15Nivolumab 14Dexamethasone 14Bevacizumab 14Gemcitabine 12Biopsy 12atezolizumab 11Temozolomide 11Paclitaxel 10venetoclax 9Pemetrexed 9Ipilimumab 9Docetaxel 9Cisplatin 9Rituximab 8Lenalidomide 8blinatumomab 7Prednisone 7Oxaliplatin 7Fluorouracil 7Capecitabine 7olaparib 6lenvatinib 6Vincristine 6Radiotherapy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × AZD5305 × 30 days × Clear all
NCT05797168 2026-06-03

FONTANA

AstraZeneca

Phase 1/2 Recruiting
506 enrolled
GynecologicThoracic

Adenocarcinoma of Lung, Ovarian Neoplasms, Endometrial Neoplasms

NCT05367440 2026-06-01

PETRANHA

AstraZeneca

Phase 1/2 Active not recruiting
174 enrolled
Genitourinary

Prostatic Neoplasms

NCT05123482 2026-05-18

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

AstraZeneca

Phase 1/2 Recruiting
460 enrolled
BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡